| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.74 | 90.0% |
| Total Income | 1.74 | 90.0% |
| Expenditure | 100.15 | 15.8% |
| PBT | — | |
| Net Profit | -93.05 | 6.0% |
| OPM | — | |
| NPM | — | |
| EPS | -0.74 | 59.3% |
Alumis Reports Q1 2026 Financial Results
15 May 2026 · 15 May, 1:48 am
Summary
Alumis Inc. reported its financial results for the quarter ended March 31, 2026. The company's collaboration revenue was $1.7 million. Research and development expenses decreased to $81.5 million, while general and administrative expenses were $18.6 million. The net loss for the quarter was $93.1 million. Alumis expects its current cash reserves to fund operations into the fourth quarter of 2027 and remains on track for NDA submission in the fourth quarter of this year.
Key Highlights
- 1
Alumis reported collaboration revenue of $1.7 million for the three months ended March 31, 2026.
- 2
Research and development expenses decreased to $81.5 million for the three months ended March 31, 2026, compared to $96.6 million for the same period in 2025.
- 3
General and administrative expenses were $18.6 million for the three months ended March 31, 2026, compared to $22.3 million for the three months ended March 31, 2025.
- 4
Net loss was $93.1 million for the three months ended March 31, 2026, compared to $99.0 million for the three months ended March 31, 2025.
- 5
Alumis anticipates that its existing cash, cash equivalents and marketable securities as of March 31, 2026 are expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.
- 6
The company plans to submit NDA for envudeucitinib in 4Q 2026.
- 7
Potentially pivotal Phase 2b topline data for envudeucitinib in systemic lupus erythematosus (SLE) is anticipated in 3Q 2026.
Management Comments
Martin Babler
"Alumis delivered a focused and productive first quarter, building on the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis and reinforcing the differentiated potential of maximal TYK2 inhibition." "We remain on track for our NDA submission in the fourth quarter of this year, as well as the potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter. With continued progress across both indications, envudeucitinib is emerging as a potential ‘pipeline in a pill’, supporting expansion into additional immune-mediated diseases. We are evaluating further indications under a unified TYK2 franchise strategy and expect to share further updates later this year."
Informational and educational content only. Not investment advice.